Exosomes Used in Drug Delivery


Excipients for mRNA Delivery Download PDF

CD Bioparticles is a high-tech company integrating professional R&D, production, and sales, providing customized solutions such as custom exosome raw materials as well as exosome drug delivery systems.

CD Bioparticles is a leading global supplier of exosomes with a dedicated research team and strong technical capabilities. Currently, exosomes research involves a variety of fields including wound healing, hair regeneration, cosmetology, biomarkers, drug delivery, and anti-cancer vaccine development, etc. CD Bioparticles is committed to providing high-purity exosome raw materials to customers worldwide. In addition, we have developed protein loading, nucleic acid loading, targeted transformation, small molecule loading of exosomes and other engineering delivery vector development services, as well as exosome in vivo and in vitro tracing, etc. to help customers solve the exosome scale-up purification, exosome drug delivery, exosome labeling and other technical difficulties.

Today we offer you:

Fully certified high-quality exosomes. This is an excellent choice for your exosomes supply if you seek to translate your R&D efforts into faster commercialization:

  • Various kinds of purified exosome products, including milk exosome, body fluid exosome, fruit and vegetable exosome, traditional Chinese medicine exosome and so on.
  • Exosome CRO service, provides exosome loading with protein and other engineered delivery vector development services.
  • Exosome isolation and purification, RNA and proteomics analysis, targeting assays and other services.

Table of Contents

  • Exosome in Biomedical Applications
  • Engineered Exosomes
  • Exosome Products

Exosome is a small membrane-bound vesicle (extracellular vesicle) that is secreted into the extracellular environment by the fusion of multive vesicle bodies (MVBs) with the cell membrane.

Exosomes Characterization:

  • Diameter of 30-150 nm.
  • Density of 1.10-1.21 g/ml.
  • Have cytoplasmic and cytomembrane components of source cells.
  • Containing a variety of proteins, mRNAs, miRNAs and lipids.

Composition of exosomes Figure 1. Composition of exosomes.1

Exosome in Biomedical Applications

Exosome-based drug delivery systems with unique properties, such as biocompatibility, less toxic, low-uptake machinery, capability to pass contents from one cell to another cell, and do not produce an immune reaction. And the unique feature that they have more tendency to accumulate in the cancerous cell than normal cells make it a good choice as drug delivery vehicles in biomedicine. Currently, exosomes have been developed for the delivery of proteins, peptides, DNA, RNA, small molecules, macromolecules, nucleic acids, etc. In addition, by modifying the targeting molecules on the exosome surface, the enrichment ability of nanoparticles at the lesion site can be improved.

Composition of exosomes Figure 2. (A)Structure of plant-derived vesicles and their bioactive applications.2
(B)Types of exosomes from different sources in the human body.3

  • Mesenchymal stem cells (MSCs)-derived exosomes (Catalog: CDE23-028)

MSC-derived exosomes themselves possess immunomodulatory, angiogenesis-promoting, and antioxidant effects. As drug carriers, exosomes can also deliver small molecule drugs and enhance cancer therapy through surface modification of targeted molecules. A research group modified the targeting peptide (CP05+P4) on the surface of Mesenchymal stem cells (MSCs)-derived exosomes to achieve specific uptake of bladder cancer and achieve precision therapy. (As shown in Figure 2)

Composition of exosomes Figure 3. MSC-derived exosomes fight cancer by modifying targeting peptides.4

  • Milk-derived exosomes (Catalog: CDE23-031)

In addition to being widely used in the medical aesthetic industry, milk-derived exosomes are also very popular in the biomedical industry. Milk-derived exosomes can regulate miRNAs to modulate the immune system, and they can also be used as drug carriers, loaded with substances such as small molecule drugs or proteins for the treatment of diseases such as breast cancer. (As shown in Figure 3)

Composition of exosomes Figure 4. Milk-derived exosomes deliver RNA for anti-cancer research.5

  • Cancer cell-derived exosomes (Catalog: CDE23-001~CDE23-007)

Cancer cell-derived exosomes are commonly used as drug carriers for targeted transport of anticancer drugs to treat the same class of tumor. A study reports that exosomes derived from cancer cells fuse preferentially with their parent cancer cells, in vitro. Systemically injected tumor-derived exosomes home to their original tumor tissues. Moreover, compared to Doxil alone, the drug-loaded exosomes showed enhanced therapeutic retention in tumor tissues and eradicated them more effectively in nude mice. This means that exosomes derived from cancer cells are capable of targeting and recognizing cancer cells, and are very promising drug carriers for cancer therapy.

Composition of exosomes Figure 5. Cancer cell-derived exosomes (HT1080 exo) for delivery of anticancer drugs.6

Engineered Exosomes

As the next generation drug delivery system, exosomes possess the following advantages:

  • As endogenous biological carriers, exosomes have low immunogenicity and few toxic side effects.
  • Exosomes can be circulated to all chambers in the body. It can even be used to deliver drugs across the blood-brain barrier.
  • Exosomes can protect internal molecules and stabilize them in the peripheral circulation, eventually reaching the target cells.

The engineered exosome platform can achieve targeted therapy at pathological sites by means of exosome-targeted modification and drug loading.

Composition of exosomes Figure 6. Engineered exosome modification functions.7

Flow Chart of Engineered Exosome Production

Composition of exosomes

Exosome Products

Catalog Product Name Description
CDE23-001 EXOMCF7 Frozen exosomes (>1x10^6) from MCF-7 human breast cancer, noninvasive cell line.
CDE23-002 EXOMDAMB231 Frozen exosomes (>1x10^6) from MDA-MB-231 human breast cancer, aggressive/invasive/metastatic cell line.
CDE23-003 EXOPC3 Frozen exosomes (>1x10^6) from PC-3 human prostate cancer cells derived from metastatic cancer cell line.
CDE23-004 EXOA549 Frozen exosomes (>1x10^6) from A549 human non-small cell lung cancer cell line.
CDE23-005 EXOH841 Frozen exosomes (>1x10^6) from H841 human small cell lung cancer cell line.
CDE23-006 EXOH196 Frozen exosomes (>1x10^6) from H196 human small cell lung cancer cell line.
CDE23-007 EXODMS114 Frozen exosomes (>1x10^6) from DMS114 human small cell lung cancer cell line.
CDE23-008 EXOPCS500-011 Frozen exosomes (>1x10^6) from PCS-500-011 human pre-adipose derived mesenchymal stem cell.
CDE23-009 EXOPCS500-012 Frozen exosomes (>1x10^6) from PCS-500-012 human bone marrow-derived mesenchymal stem cell line.
CDE23-031 EXOMILK Frozen exosomes (>1x10^6) from Milk.
CDE23-032 EXO293T Frozen exosomes (>1x10^6) from 293T Cell.
CDE23-033 EXONK CELL Frozen exosomes (>1x10^6) from NK Cell (Human).
CDE23-042 EXOONION Frozen exosomes (>1x10^6) from onion juice.
CDE23-043 EXOGINGER Frozen exosomes (>1x10^6) from ginger.
CDE23-044 EXOGARLIC Frozen exosomes (>1x10^6) from garlic.
CDE23-045 EXOCELERY Frozen exosomes (>1x10^6) from celery.
CDE23-046 EXOTOMATO Frozen exosomes (>1x10^6) from tomato.
CDE23-047 EXOALOE Frozen exosomes (>1x10^6) from aloe.
CDE23-048 EXOCUCUMBER Frozen exosomes (>1x10^6) from cucumber.
CDE23-049 EXOPOMEGRANATE Frozen exosomes (>1x10^6) from pomegranate.
CDE23-050 TargetExo-RVG (Personalization) Exosome surface modification of the targeting peptide RVG.
CDE23-051 TargetExo-iRGD (Personalization) Exosome surface modification of the targeting peptide iRGD.
CDE23-052 TargetExo-GE11 (Personalization) Exosome surface modification of the targeting peptide GE11.
CDE23-053 TargetExo-tLyp-1 (Personalization) Exosome surface modification of the targeting peptide tLyp-1.
CDE23-054 TargetExo-HER2 (Personalization) Exosome surface modification of the targeting peptide HER2.
CDE23-055 TargetExo-DSS6 (Personalization) Exosome surface modification of the targeting peptide DSS6.
CDE23-056 TargetExo-E7 (Personalization) Exosome surface modification of the targeting peptide E7.
CDE23-057 TargetExo-IMTP (Personalization) Exosome surface modification of the targeting peptide IMTP.
CDE23-058 TargetExo-LTH (Personalization) Exosome surface modification of the targeting peptide LTH.

References
1. Kalluri R, et al.; The biology, function, and biomedical applications of exosomes. Science. 2020, 367: 6478.
2. Cao M, et al.; Plant exosome nanovesicles (PENs): green delivery platforms. Materials Horizons. 2023, 10(10): 3857-3873.
3. Xie D, et al.; Nucleic acids and proteins carried by exosomes from various sources: Potential role in liver diseases. Frontiers in Physiology. 2022, 13: 957036-957054.
4. Yang J, et al.; Engineered exosome-mediated cobalt sulfide quantum dot targeted delivery for photothermal and chemodynamic anticancer therapy. Journal of Drug Delivery Science and Technology. 2023, 83:104441.
5. Aqil F, et al.; Milk exosomes-Natural nanoparticles for siRNA delivery. Cancer Letters. 2019, 449: 186-195.
6. Qiao L, et al.; Tumor cell-derived exosomes home to their cells of origin and can be used as Trojan horses to deliver cancer drugs. Theranostics. 2020, 10(8):3474-3487.
7. Xiong M, et al.; The novel mechanisms and applications of exosomes in dermatology and cutaneous medical aesthetics. Pharmacological Research. 2021,166: 105490-105504.

Contact Us

    USA

    UK

Fill out the form below
to receive a quote

GET A QUOTE

  • (USA)
  • (Europe)
Cookie Policy | Privacy Policy | Copyright © 2024 CD Bioparticles. All rights reserved.
0
Inquiry Basket
Inquiry